window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 29, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

molecular diagnostics

  • Diagnostics,Gastroenterology,Genomics and sequencing,Partnerships & Funding,Technology and platforms

    Primerdesign and Origin partner on rectal mucus DNA extraction for colorectal cancer detection

    Primerdesign and Origin Sciences partner to develop a DNA extraction [...]

    March 25, 2026
  • Diagnostics,Genomics and sequencing,Research & Development,Technology and platforms

    New England Biolabs launches Monarch Mag Cell-free DNA extraction kit for scalable cfDNA isolation

    New England Biolabs has launched the Monarch Mag Cell-free DNA [...]

    February 15, 2026
  • Diagnostics,Infectious Diseases,Medical devices,Technology and platforms

    En Carta Diagnostics receives FDA breakthrough device designation for Lyme disease test

    En Carta Diagnostics has received FDA Breakthrough Device Designation for [...]

    January 30, 2026
  • Clinical Trials,Infectious Diseases,Research & Development

    Cytespace Africa Labs expands molecular testing capacity to support clinical trials across sub-Saharan Africa

    Cytespace Africa Laboratories has expanded its molecular testing capacity to [...]

    January 21, 2026
  • Oncology,Patient Centricity,Regulatory Affairs

    UK clears Mainz Biomed’s ColoAlert for colorectal cancer screening

    Mainz Biomed has received official registration from the UK Medicines [...]

    September 8, 2025
  • Medical devices,Oncology,Patient Centricity,Regulatory Affairs

    Refold AI emerges to simplify enterprise integrations with agentic platform

    Mainz Biomed N.V., a molecular genetics diagnostic company specializing in [...]

    August 14, 2025
  • Clinical Trials,Drug Development,Market Access & Commercialization,Oncology,Partnerships & Funding,Precision medicine,Regulatory Affairs,Research & Development,Technology and platforms

    Mainz Biomed targets US approval for next-gen CRC test and expands into pancreatic cancer

    Mainz Biomed says it is preparing to launch a pivotal [...]

    July 18, 2025
  • Oncology,Technology and platforms

    Mainz Biomed launches feasibility study to assess pancreatic cancer biomarker panel

    Mainz Biomed has initiated a feasibility study as part of [...]

    June 11, 2025
  • Artificial Intelligence,Drug Development,Partnerships & Funding,Precision medicine,Technology and platforms

    Biostate AI raises $12M to build the ‘Netflix’ of molecular diagnostics using RNAseq and GenAI

    Biostate AI has raised $12 million in Series A funding [...]

    May 23, 2025
  • Partnerships & Funding

    Mainz Biomed and EDX Medical Group form technology partnership to expand access to molecular cancer diagnostics in the UK

    Mainz Biomed, a molecular diagnostics company focused on the early [...]

    May 2, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • ARTCLINE completes enrolment in septic shock trial for ARTICE therapy
    Categories: Biotech, Cell & Gene Therapy, Clinical Development, Clinical Trials, Infectious Diseases, Pharmaceuticals and therapeutics
  • SGD Pharma highlights GLP-1 demand, supply chain pressure and sustainability focus at DCAT Week
    Categories: CDMOs & Manufacturing, Healthcare leadership, Market Access & Commercialization, Pharmaceuticals and therapeutics, Supply Chain & Logistics
  • ISS National Lab research advances DNA-inspired cancer nanomaterials for chemotherapy and immunotherapy development
    Categories: Drug Delivery & Formulation, Drug Development, Oncology, Pharmaceuticals and therapeutics, Research & Development, Technology and platforms
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top